X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

By Katie Koziara  |    January 19, 2023
This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...   Read More

340B program continues to drive shift in care to more expensive hospital settings

By Nicole Longo  |    December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...   Read More

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

By Nicole Longo  |    November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...   Read More

Three ways 340B is failing vulnerable patients

By Nicole Longo  |    October 20, 2022
The 340B Drug Pricing Program is 30 years old this year, but as The New York Times recently spelled out, the program has become a profit engine for large health systems over the years instead of a...   Read More

If patients aren’t benefiting from the 340B program, who is?

By Nicole Longo  |    October 6, 2022
The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally...   Read More

New data: The 340B program is driving up costs for patients and our health care system

By Nicole Longo  |    September 15, 2022
Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided...   Read More

Word of the Month: 340B covered entity

By Nicole Longo  |    August 29, 2022
What is a 340B covered entity?   Read More

340B program remains second largest federal drug program, yet little solid evidence of benefits to patient

By Nicole Longo  |    June 30, 2022
Over the three decades since Congress created the 340B drug pricing program, we’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The...   Read More

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

By Nicole Longo  |    June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....   Read More

New research finds gaps in charity care provided by 340B hospitals

By Nicole Longo  |    June 2, 2022
The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates